CDC (US Centers for Disease Control) funds continuous glucose monitor development:
This article was originally published in Clinica
SpectRx has received further funds from the US Centers for Disease Control and Prevention (CDC) to adapt its investigational bloodless continuous glucose monitor for use in children and the elderly. The $338,000 grant raises the total CDC funding for the project to almost $1 million, says the Norcross, Georgia firm. The device, which is worn on top of the skin, monitors glucose in interstitial fluid. SpectRx is developing it with Abbott Laboratories, which holds worldwide marketing rights for the product.